Evidence map›Paper›PMID 27294004›Full record

ArticleAmerican journal of cancer research2016

Nanoparticle-based targeted gene therapy for lung cancer.

Hung-Yen Lee, Kamal A Mohammed, Najmunnisa Nasreen

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. The Nanosystems Involved in Treating Lung Cancer.Life (Basel, Switzerland) · 2021
    Review
  16. Article
  17. Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  18. Immune cell engineering: opportunities in lung cancer therapeutics.Drug delivery and translational research · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hung-Yen LeeDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of Florida P. O. Box 100225, USA.
Kamal A MohammedDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA; North Florida/South Georgia Veterans Health System, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA.
Najmunnisa NasreenDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA; North Florida/South Georgia Veterans Health System, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite striking insights on lung cancer progression, and cutting-edge therapeutic approaches the survival of patients with lung cancer, remains poor. In recent years, targeted gene therapy with nanoparticles is one of the most rapidly evolving and extensive areas of research for lung cancer. The major goal of targeted gene therapy is to bring forward a safe and efficient treatment to cancer patients via specifically targeting and deterring cancer cells in the body. To achieve high therapeutic efficacy of gene delivery, various carriers have been engineered and developed to provide protection to the genetic materials and efficient delivery to targeted cancer cells. Nanoparticles play an important role in the area of drug delivery and have been widely applied in cancer treatments for the purposes of controlled release and cancer cell targeting. Nanoparticles composed of artificial polymers, proteins, polysaccharides and lipids have been developed for the delivery of therapeutic deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequences to target cancer. In addition, the effectiveness of cancer targeting has been enhanced by surface modification or conjugation with biomolecules on the surface of nanoparticles. In this review article we provide an overview on the latest developments in nanoparticle-based targeted gene therapy for lung cancers. Firstly, we outline the conventional therapies and discuss strategies for targeted gene therapy using nanoparticles. Secondly, we provide the most representative and recent researches in lung cancers including malignant pleural mesothelioma, mainly focusing on the application of Polymeric, Lipid-based, and Metal-based nanoparticles. Finally, we discuss current achievements and future challenges.

Indexed as

EphA2EphrinA1Lung cancermalignant mesotheliomananoparticlestargeted gene therapy

Identifiers

PMID27294004
PMCPMC4889725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.